Rakuten Medical Secures $119M in Series E Funding
March 11, 2024, 12:02 pm
Location: United States, California, San Diego
Employees: 201-500
Founded date: 2010
Total raised: $285M
Rakuten Medical, a biotechnology company focused on precision therapies for cancer treatment, has successfully raised $119M in a Series E funding round. The funding was provided by Hikma, Mizuho Bank, Dai-ichi Life, SBI Group, Rakuten Group, and Chairman and CEO Mickey Mikitani. This financial boost will be used to advance the development of the company's pipeline.
The company, with its U.S. headquarters in San Diego, is making strides in the field of precision medicine. The addition of Mazen Darwazah of Hikma to its board signifies a strategic move towards further growth and innovation.
Rakuten Medical's Alluminox™ platform, which targets cancer cells with precision, has shown promising results in pre-clinical studies. The company's focus on accelerating its global Phase 3 clinical trial and exploring new treatment combinations highlights its commitment to advancing cancer therapies.
With offices in multiple countries, including the United States, Japan, Taiwan, Switzerland, and India, Rakuten Medical is poised to make a significant impact in the field of oncology. The company's dedication to improving patient outcomes and developing innovative treatment technologies sets it apart in the biotechnology landscape.
As Rakuten Medical continues to push the boundaries of cancer treatment, the recent funding round solidifies its position as a key player in the fight against this devastating disease. With a focus on precision and innovation, Rakuten Medical is paving the way for a brighter future in cancer care.
The company, with its U.S. headquarters in San Diego, is making strides in the field of precision medicine. The addition of Mazen Darwazah of Hikma to its board signifies a strategic move towards further growth and innovation.
Rakuten Medical's Alluminox™ platform, which targets cancer cells with precision, has shown promising results in pre-clinical studies. The company's focus on accelerating its global Phase 3 clinical trial and exploring new treatment combinations highlights its commitment to advancing cancer therapies.
With offices in multiple countries, including the United States, Japan, Taiwan, Switzerland, and India, Rakuten Medical is poised to make a significant impact in the field of oncology. The company's dedication to improving patient outcomes and developing innovative treatment technologies sets it apart in the biotechnology landscape.
As Rakuten Medical continues to push the boundaries of cancer treatment, the recent funding round solidifies its position as a key player in the fight against this devastating disease. With a focus on precision and innovation, Rakuten Medical is paving the way for a brighter future in cancer care.